Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 19/20 | 0.56 |
| ▸ | TTBK2 | Q6IQ55 | 17/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28048062 | 0.94 | TTBK1 (0.64) | TTBK1TTBK2KDRTEK | |
| SCHEMBL4913780 | 0.88 | TTBK1 (0.62) | TTBK1TTBK2KDR | |
| SCHEMBL4923711 | 0.84 | TTBK1 (0.64) | TTBK1TTBK2 | |
| SCHEMBL30677302 | 0.83 | EGFR (0.54) | TTBK1TTBK2 | |
| SCHEMBL4922514 | 0.83 | MKNK1 (0.61) | TTBK1TTBK2 | |
| SCHEMBL4926094 | 0.83 | EGFR (0.54) | TTBK1TTBK2 | |
| SCHEMBL4921635 | 0.83 | MKNK1 (0.54) | TTBK1TTBK2KDR | |
| SCHEMBL4498466 | 0.83 | TTBK1 (0.59) | TTBK1TTBK2KDR | |
| SCHEMBL4923801 | 0.83 | TTBK1 (0.59) | TTBK1TTBK2KDR | |
| SCHEMBL28048041 | 0.82 | TTBK1 (0.47) | TTBK1TTBK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518965-B2 | Compositions and methods for treating cancer | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518965-B2 | Compositions and methods for treating cancer | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165365-A1 | Compositions and Methods for Treating Cancer | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165365-A1 | Compositions and Methods for Treating Cancer | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2011016952-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165365-A1 | Compositions and Methods for Treating Cancer | MKI67, DCX, NES | TTBK1 1106/4885TTBK2 822/4885KDR 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.